Avacta announces AVA6000 dose escalation results
Candidate is a cancer therapy that has been chemically modified with Avacta’s pre|CISION platform
Read Moreby John Pinching | Jun 21, 2023 | News | 0
Candidate is a cancer therapy that has been chemically modified with Avacta’s pre|CISION platform
Read Moreby John Pinching | Apr 5, 2023 | News | 0
Individual receives AVA6000 treatment as part of additional dose escalating study
Read Moreby John Pinching | Sep 1, 2022 | News | 0
Pro-doxorubicin will advance to the fourth dose following a positive review of safety and tolerability
Read Moreby John Pinching | Jun 29, 2022 | News | 0
AVA6000 is a novel form of doxorubicin that has been modified using Avacta’s delivery platform to improve safety
Read Moreby Lucy Parsons | Feb 19, 2021 | News | 0
AVA6000 is pro-drug form of the chemotherapy doxorubicin, modified using Avacta’s pre|CISION chemistry
Read Moreby Selina McKee | Apr 9, 2020 | News | 0
The firms will develop and manufacture an Affimer-based point-of-care rapid test for screening large populations for COVID-19 infection
Read Moreby Anna Smith | Oct 10, 2019 | News | 0
The partnership will focus on developing potent Affimer-drug conjugates.
Read Moreby Selina McKee | Jan 16, 2018 | News | 0
UK companies Avacta and Glythera have sealed a licensing deal to develop drug conjugates using their combined technologies.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
